Actos, or pioglitazone, is a widely prescribed oral antidiabetic agent. It is an inhibitor of glucose and lipid metabolism, with therapeutic effects on insulin resistance, lipid profiles, and cardiovascular function in a dose-dependent manner. The use of pioglitazone is associated with gastrointestinal side effects, such as nausea, vomiting, diarrhea, and abdominal pain. In contrast, the administration of metformin, a widely used drug for treating type 2 diabetes, is associated with serious cardiovascular events including myocardial infarction, stroke, and cardiovascular-related death. The safety of metformin was previously demonstrated in patients with type 1 diabetes [
,
]. The safety of metformin was demonstrated in patients with type 1 diabetes who received insulin or metformin in a dose-dependent manner, with a mean daily dose of 15–25 mg/day [
Metformin has also been reported to be associated with cardiovascular events, including myocardial infarction and cardiac revascularization procedures. In a clinical study, metformin induced a significant reduction in the incidence of coronary events (including myocardial infarction and stroke) in patients with type 1 diabetes. Furthermore, metformin was found to be associated with the development of cardiovascular-related deaths [
The mechanism of action of metformin is related to inhibition of the glucose-dependent HMG-CoA reductase enzyme, which leads to the accumulation of glucose in the liver and liver efflux pumps, resulting in reduced hepatic glucose production and an increased lipid accumulation [
Metformin has also been shown to have a beneficial effect in the treatment of type 2 diabetes mellitus [
Metformin exerts its anti-diabetic effects by inhibiting the hepatic gluconeogenesis and hepatic gluconeogenesis by affecting the expression of hepatic insulin-like growth factor 1 receptor (Lir1), a critical signaling molecule, and the expression of glucose transporter 1 (GITS1) and glucose-dependent transporter (GITS2) in peripheral tissues [
Metformin has been associated with an enhanced expression of hepatic GLUT-1, a key component of hepatic stellate cells, in diabetic rats and its mechanism of action is related to its pharmacological action [
The mechanism of action of metformin is related to the inhibition of glucose uptake and utilization, resulting in decreased glucagon-like peptide-1 (GLP-1) secretion from peripheral tissues [
Metformin is an orally active drug that is rapidly absorbed in the form of oral tablets, and its plasma concentration is approximately 5.8 µg/mL in healthy subjects [
Metformin has also been reported to be highly selective for the GLUT-1 and GLUT-2 receptors, which are involved in insulin-induced GLUT-1 secretion and GLUT-2 secretion in human chorionic gonads, suggesting that metformin exerts its therapeutic effects through the blockade of GLUT-1 and GLUT-2 channels [
The mechanism of action of metformin is related to the inhibition of hepatic gluconeogenesis and hepatic gluconeogenesis, resulting in decreased hepatic glucose production and increased hepatic lipid accumulation. The mechanism of action of metformin is also related to the upregulation of the GLUT-1 and GLUT-2 receptors, which are involved in the upregulation of the insulin-induced insulin-dependent insulinotropic polypeptide (IP)-1 receptor [
Metformin has also been shown to be associated with the development of type 1 diabetes [
Metformin has also been reported to inhibit hepatic gluconeogenesis and hepatic gluconeogenesis, which may be related to its inhibitory action on the insulin receptor [
A new study from the Cleveland Clinic Foundation indicates that the popular anti-diabetes drug Actos can help in people with type 2 diabetes.
Actos, a diabetes drug that blocks the hormone that makes the cells of the pancreas grow, is FDA-approved to treat Type 2 diabetes. The drug has also been studied for its potential in reducing blood sugar in people with type 2 diabetes.
In the new study, published in the journal, researchers studied patients with type 2 diabetes who had not been treated with the drug for a year. They found that Actos could help in patients with type 2 diabetes.
The study, presented today at the American Diabetes Association annual meeting in San Diego, focused on patients who had type 2 diabetes, as well as those who had not been treated with Actos.
“Our study demonstrates that Actos can be a potential treatment for Type 2 diabetes,” said co-author Dr. David J. Hahn, M. D., and director of the Center for Biomedical Drug Development in Cleveland, Ohio.
Actos has been used to help treat Type 2 diabetes for decades. Hahn explained that Actos was initially developed as a diabetes drug.
Actos is a non-steroidal anti-inflammatory drug (NSAID) that blocks the body’s production of the hormone dihydrotestosterone (DHT). The drug has been shown to lower the level of DHT in people with type 2 diabetes.
The results, published earlier this month in the Journal of the American Medical Association, showed that the drug increased the levels of DHT in blood cells of patients with type 2 diabetes.
“These findings support the idea that Actos can help in treating Type 2 diabetes,” Hahn said.
The study was funded by Boehringer Ingelheim, which uses data from the Cleveland Clinic’s Center for Drug Evaluation and Research.
“This is the first study to show that Actos can help in treating Type 2 diabetes,” said Dr. Michael M. Leckman, M. D., a director of the Center for Drug Evaluation and Research. “The results of the study support the notion that Actos can be a potential treatment for Type 2 diabetes.”
The researchers also found that Actos may have an effect on patients who take it as long as two years after starting the drug. The drug has been used in studies for the treatment of type 2 diabetes, and studies have shown that Actos can help in patients with type 2 diabetes.
“In fact, this is one of the first studies to show that Actos can be an effective treatment for type 2 diabetes,” said Dr. Leckman.
The researchers said that the results may be because people who took Actos for more than two years, had more blood glucose levels and were more likely to have diabetes.
“We are very excited to see that this study is showing that Actos can help in people with type 2 diabetes,” said Hahn.
The Cleveland Clinic is an independent organization that provides research-based education and outreach to individuals with diabetes. Its main research interest is in the use of medication for diabetes.
“As a diabetes patient, I would like to welcome this study,” Hahn said. “We’re excited to see that this study shows that Actos can help in people with type 2 diabetes.”
Originally published in the February 6, 2015, issue of the American Diabetes Association.
Photo credit: Dr. Michael Leckman, M. D. via Associated PressImage: (Associated Press)
For more from the Cleveland Clinic, visit
.VIDEO
A new study from the Cleveland Clinic Foundation shows that the popular anti-diabetes drug Actos can help in people with type 2 diabetes.The new study, published in the journal, “The Use of Actos in the Treatment of Type 2 Diabetes,” investigated the use of Actos in people with type 2 diabetes.
Dr. David Hahn, M. D., director of the Center for Drug Evaluation and Research, presented the findings at the American Diabetes Association annual meeting in San Diego.
Actos® (pioglitazone hydrochloride) is a novel class of oral antidiabetic medications, with a long history of use and well-documented benefits. This article discusses the pharmacological profile of Actos and the role it has played in the treatment of type 2 diabetes mellitus. The use of Actos as a diabetes treatment has been under significant scrutiny as a result of various clinical studies and the lack of a comprehensive clinical pharmacology, data, and results of clinical trials. A key advantage of Actos is its rapid onset of action, which can be as rapid as 15 minutes to half a minute in humans. However, the development of drug interactions has resulted in drug side effects, including decreased appetite and weight gain, which can lead to serious health complications.
The use of Actos as a diabetes treatment has been associated with gastrointestinal issues. Gastrointestinal issues are a major concern in patients with type 2 diabetes mellitus. These are defined as changes in the amount of sugar produced, including pancreatic and small bowel hyperplasia, in patients treated with pioglitazone. It is not clear which factors contribute to the increased risk of these symptoms and whether Actos is associated with these effects. We are aware that Actos has been associated with some gastrointestinal adverse effects and that other pioglitazone products have also been associated with these issues. However, it is likely that Actos is responsible for these gastrointestinal issues.
The use of Actos as a diabetes treatment has been associated with an increased incidence of type 2 diabetes mellitus and complications in patients with type 1 diabetes mellitus. Actos has been reported to be associated with increased risk of major gastrointestinal (GI) adverse events (AEs) including GI bleeding, ulceration, and perforation of the esophagus and stomach in patients who are diabetic. It has been suggested that Actos may be associated with an increased risk of GI bleeding and perforation of the esophagus and stomach associated with its use. Furthermore, there have been concerns about the increased incidence of serious AEs, including GI bleeding and ulceration, associated with Actos use. A causal relationship between Actos use and a serious AEs has not been established.
The use of Actos as a diabetes treatment has been associated with an increased risk of serious AEs including GI bleeding, ulceration, and perforation of the esophagus and stomach in patients who are diabetic. Furthermore, the use of Actos as a diabetes treatment has been associated with a higher incidence of GI bleeding, ulceration, and perforation of the esophagus and stomach in patients who are diabetic. Although it is possible that Actos may be associated with serious AEs, there have been concerns with regard to its effects on the gastrointestinal system. To the best of our knowledge, there have been no studies that investigated the association between Actos use and serious AEs. This study aimed to determine the incidence of serious AEs in patients treated as an adjunct to diet and exercise and to investigate the association between Actos use and serious AEs. A prospective cohort study was conducted at a regional center in Tamburep, Egypt. The primary outcome was the incidence of serious AEs. The secondary outcomes included the incidence of the following: serious GI bleeding, ulceration, and perforation (included in the event of ulceration or perforation in the event of GI bleeding), serious upper GI symptoms, and GI bleeding in the event of severe upper GI symptoms (ulceration, ulceration, or perforation). Patients were treated as an adjunct to diet and exercise with or without Actos as the primary outcome measure. All patients provided written informed consent. The study was approved by the Institutional Review Board of Tamburep (IRB No. 60538).
The majority of patients (65%) were female. The average age was 53 years (range, 15–75 years). Ninety three patients (91%) were diagnosed as diabetic (type 1) at baseline.
During the period from January 1, 1999 to August 31, 2015, the average age was 48.8 (range, 15–71 years). The majority of patients were female. Ninety three patients (81%) were diagnosed as diabetic at baseline.
In total, 890 patients (84%) met the inclusion criteria. Of these, 790 (84%) were diagnosed as having type 2 diabetes.
In total, 890 patients (84%) were treated with pioglitazone. Of the patients, 98% met the inclusion criteria.
Acyclovir is an antiviral medication used to treat infections caused by the herpes virus. It is an orally active drug that is available in the form of tablets and oral suspension.
Acyclovir works by preventing the replication of the herpes virus. This helps the virus to spread and to heal itself.
Acyclovir and Actos are two different drugs that have the same active ingredient. They both work by slowing down the virus's growth and replication and are both used for the treatment of herpes infections.
Acyclovir and Actos are both antiviral medications used to treat herpes infections. Acyclovir, like other medications, is used to treat viral infections such as cold sores, genital herpes, and shingles. Actos, on the other hand, is used to treat herpes infections such as cold sores, shingles, and chickenpox.
Acyclovir and Actos are both used to treat herpes infections. Acyclovir is an orally active drug that is available in the form of tablets and oral suspension. It works by slowing down the virus's growth and replication and to promote healing.
However, Acyclovir can also be used in combination with other drugs, such as, to treat chickenpox or chickenpox to prevent the virus from spreading to other people. It is also used to treat herpes infections, such as genital herpes and shingles.
Acyclovir, like other medications, is an oral drug that is available in the form of tablets and oral suspensions. It works by inhibiting the virus's growth and replication. This helps the virus to spread and heal itself.
However, Actos can also be used in combination with other drugs, such as, to treat chickenpox or chickenpox to prevent the virus from spreading to other people. It is also used to treat herpes infections, such as cold sores, shingles, and genital herpes.
Acyclovir and Actos are both used to treat viral infections. It works by preventing the virus from spreading and to heal itself.
It is important to note that Acyclovir can be taken by mouth, as it can affect the absorption of the drug in the body. Therefore, it is recommended to take the medication with food, as it can reduce the effectiveness of the drug. It is also important to follow the recommended dosage and administration instructions of the doctor.
Stade de France Pharmacy